Literature DB >> 8887127

Effect of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion.

J E Ruiz1, J Y Kwak, L Baum, A Gilman-Sachs, K D Beaman, Y B Kim, A E Beer.   

Abstract

Intravenous immunoglobulin (IVIg) has been used to treat women with recurrent spontaneous abortion (RSA), particularly for women with elevated natural killer (NK) cells. We investigated the effect of IVIg on peripheral blood NK cell activity in vitro in women with RSA. 51Cr-release assays using K562 in the presence of varying concentrations of IVIg were performed using PBL from 16 women with RSA. Antibody dependent cellular cytotoxicity (ADCC) was evaluated using Daudi cells. Effectors and targets were preincubated with IVIg. Binding of IVIg to K562 and Daudi was evaluated by flow cytometry. The effect of K562 absorbed IVIg on NK activity was compared to that of non-absorbed IVIg. NK cytotoxicity and ADCC in the presence of F(ab')2 fragments were compared with those in the presence of intact IVIg. IVIg produced a significant, dose dependent inhibition of NK activity in vitro. Inhibition of NK activity occurred when effectors but not targets were preincubated with IVIg. IVIg binds to K562 and Daudi. IVIg increased ADCC when targets but not effectors were incubated with IVIg. K562 absorbed IVIg produced more inhibition of NK cytotoxicity than non-absorbed IVIg. Suppression of NK cytotoxicity by F(ab')2 was as effective as that of IVIg. However, F(ab')2 did not increase ADCC. IVIg effectively reduces peripheral blood NK cytotoxicity in vitro. Inhibition of NK cytotoxicity is mediated at the effector cell level through the antigen binding portion of the immunoglobulins. Women with RSA and elevated NK cells may benefit from IVIg treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887127     DOI: 10.1016/0165-0378(96)00969-2

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  11 in total

Review 1.  Intravenous immunoglobulin and recurrent pregnancy loss.

Authors:  Howard J A Carp; Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  Immunotherapy for recurrent miscarriage.

Authors:  Luchin F Wong; T Flint Porter; James R Scott
Journal:  Cochrane Database Syst Rev       Date:  2014-10-21

Review 3.  Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF).

Authors:  David A Clark; Carolyn B Coulam; Raphael B Stricker
Journal:  J Assist Reprod Genet       Date:  2006-01-19       Impact factor: 3.412

Review 4.  NK cells, autoantibodies, and immunologic infertility: a complex interplay.

Authors:  Caterina De Carolis; Carlo Perricone; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

5.  Neutralization of measles virus infectivity and antibody-dependent cell-mediated cytotoxicity activity against an Epstein-Barr virus-infected cell line by intravenous immunoglobulin G [corrected].

Authors:  MariCarmen Colomar; Irene Puga; Maite López; Marta Massot; Juan I Jorquera; Manuel Reina; Senen Vilaró; Enric Espel
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

6.  Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions in vitro.

Authors:  Amandine Pradier; Maria Papaserafeim; Ning Li; Anke Rietveld; Charlotte Kaestel; Lyssia Gruaz; Cédric Vonarburg; Rolf Spirig; Gisella L Puga Yung; Jörg D Seebach
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

Review 7.  Role of Decidual Natural Killer Cells in Human Pregnancy and Related Pregnancy Complications.

Authors:  Xiuhong Zhang; Haiming Wei
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

8.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

9.  ART implantation failure and miscarriage in patients with elevated intracellular cytokine ratios: response to immune support therapy.

Authors:  Conor Harrity; Lyuda Shkrobot; David Walsh; Kevin Marron
Journal:  Fertil Res Pract       Date:  2018-10-17

10.  Intralipid therapy and adverse reproductive outcome: is there any evidence?

Authors:  Parijot Kumar; Kevin Marron; Conor Harrity
Journal:  Reprod Fertil       Date:  2021-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.